2005 PRETEXT: a revised staging system for primary malignant liver tumours of childhood developed by the SIOPEL group

Roebuck, Derek J.; Aronson, Daniël C.; Clapuyt, Philippe; Czauderna, Piotr; Goyet, Jean de Ville de; Gauthier, F.; MacKinlay, Gordon A.; Maibach, Rudolf; McHugh, Kieran; Olsen, Øystein E.; Otte, Jean-Bernard; Pariente, D.; Plaschkes, J.; Childs, Margaret; Perilongo, Giorgio

doi:10.1007/s00247-006-0361-5

Cited by 312 publications

(251 citation statements)

References 22 publications

Supporting

Mentioning

232

Contrasting

Unclassified

Order By: Relevance

“…It distinguishes four PRETEXT stages but also uses other parameters to assess the spread of the tumor beyond the liver (lymph node metastases, portal vein involvement, involvement of the inferior vena cava and/or hepatic veins, extrahepatic abdominal disease, tumor rupture or intraperitoneal haemorrhage disease, distant metastases) (15). On the other hand, the POSTTEXT staging system was developed by the COG group.…”

Section: Abstract Hepatoblastoma Is the Most Common Pediatric Livermentioning

confidence: 99%

Therapeutic Innovations for Targeting Hepatoblastoma

Garnier

Ilmer

Kappler

et al. 2016

View full text Add to dashboard Cite

Section: Abstract Hepatoblastoma Is the Most Common Pediatric Livermentioning

confidence: 99%

Therapeutic Innovations for Targeting Hepatoblastoma

Garnier

Ilmer

Kappler

et al. 2016

View full text Add to dashboard Cite

“…This system divides the liver into four sectors, an anterior and a posterior sector on the right and a medial and a lateral sector on the left ( Table 2). The Children's Oncology Group (COG) adopted a different system based mostly on surgical findings [38][39][40] . In SIOPEL protocol, a tumor biopsy is required to confirm diagnosis before starting chemotherapy and this does not upstage a patient if a subsequent complete resection is performed.…”

Section: Fernandez-pineda I Et Al Liver Tumors In Infantsmentioning

confidence: 99%

Differential diagnosis and management of liver tumors in infants

Fernández-Pineda

Cabello-Laureano

2014

WJH

View full text Add to dashboard Cite

During the first year of life, most of the liver neoplasms are benign in origin, but some of these histologically benign lesions may be challenging in their management. Although most hepatic hemangiomas can be safely observed until involution is documented, some patients will need treatment due to progressive hepatomegaly, hypothyroidism and/or cardiac failure. Large mesenchymal hamartomas may require extensive hepatic resection and an appropriate surgical plan is critical to obtain good results. For malignant neoplasms such as hepatoblastoma, complete surgical resection is the mainstay of curative therapy. The decision about whether to perform an upfront or delayed resection of a primary liver malignant tumor is based on many considerations, including the ease of resection, surgical expertise, tumor histology and stage, and the likely chemosensitivity of the tumor. This article reviews the initial management of the more common hepatic tumors of infancy, focusing on the differential diagnosis and treatment options.

show abstract

“…The European staging system considers only the pretreatment extent of disease (i.e., the PRETreatment EXTent of disease scoring system [PRETEXT]), and was developed by the Childhood Liver Tumor Strategy Group of the Société Internationale d'Oncologie Pédiatrique, SIOPEL [40]. As shown in Figure 3, the PRETEXT staging system divides the liver into four sectors, and the number of segments involved by tumor indicates stage.…”

Section: Stagingmentioning

confidence: 99%

Liver Tumors in Children

2008

View full text Add to dashboard Cite

After completing this course, the reader should be able to:1. Describe the current epidemiologic trends in hepatoblastoma.2. Identify the genetic syndromes that are seen in a subset of liver tumors.3. Assess the need for complete tumor resection in the treatment of liver tumors in children as well as the increasingly important option of liver transplantation for those patients with unresectable tumors.4. Discuss the impact of the hepatitis vaccine in reducing the incidence of hepatocellular carcinoma.5. Explain the prognostic impact of different histologic subtypes of hepatoblastoma.6. Promote the need for future clinical trials in testing new agents for hepatocellular carcinoma in children.7. Employ the different staging systems used in liver tumors, including the traditional North American postsurgical staging system and the European presurgical staging system using imaging.This article is available for continuing medical education credit at CME.TheOncologist.com. CME CME ABSTRACT

show abstract

2005 PRETEXT: a revised staging system for primary malignant liver tumours of childhood developed by the SIOPEL group

Cited by 312 publications

References 22 publications

Therapeutic Innovations for Targeting Hepatoblastoma

Therapeutic Innovations for Targeting Hepatoblastoma

Differential diagnosis and management of liver tumors in infants

Liver Tumors in Children

Contact Info

Product

Resources

About